Using stem cells to treat lung disease in patients with connective tissue disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of adipose-derived mesenchymal stem cells (AD-MSC) in patients suffering from connective tissue disease-associated interstitial lung disease (CTD-ILD). The study will involve administering intravenous infusions of AD-MSC to patients who have refractory or rapidly progressive forms of ILD. Participants will undergo a series of infusions, with monitoring for adverse events and assessment of lung function over time. The trial is designed to determine whether this innovative stem cell therapy can improve lung function and overall outcomes in affected patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adult subjects aged between 20 and 80 years who meet the diagnostic criteria for connective tissue diseases such as dermatomyositis, polymyositis, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, or Sjogren's syndrome.
2. Subjects with refractory or progressive fibrotic interstitial lung disease: Subjects have been treated with steroids and potent immunosuppressants for more than 24 months with continued deterioration of lung function or lung lesions on CT scan (defined as a forced vital capacity (FVC) decline of more than 10% from baseline, an FVC decline of 5-10% with a diffusing capacity for carbon monoxide (DLCO) decline of more than 15% from baseline, or enlargement of lung lesions on CT scan) ; Or subjects with rapidly progressive interstitial lung disease: treated with high-dose steroids (above 0.8 mg/kg/day) and potent immunosuppressants for more than 3 months with continued deterioration of lung function or lung lesions on CT scan (defined as an FVC decline of more than 5% from baseline, a DLCO decline of more than 10% from baseline, or enlargement of lung lesions on CT scan); subjects with rapidly worsening condition: Onset of pulmonary symptoms within one month, gradual worsening of dyspnea and decreased blood oxygen levels, or enlargement of lung lesions.
3. Subjects must have a well-established family support system confirmed by interviews with the principal investigator and social worker.
4. Negative high-sensitivity urine pregnancy test before the trial.
5. Agree to use effective contraceptive measures during the trial (e.g., taking contraceptive pills or using intrauterine devices one month before the trial).

Exclusion Criteria:

1. Subjects who are unwilling to sign the informed consent form after detailed explanation by the physician.
2. Patients younger than 20 or older than 80 years who show improvement in lung function or lung lesions on CT scan after 6 months of treatment with steroids and immunosuppressants.
3. Women who are pregnant or breastfeeding, and women of childbearing age who do not use contraception.
4. Subjects with abnormal liver function (serum GOT and GPT levels more than twice the upper limit of 40 units, except those caused by inflammatory myopathy) or poor kidney function (serum creatinine levels exceeding 1.4 units).
5. Subjects with immune deficiencies such as HIV/AIDS or other specific conditions (e.g., those diagnosed with notifiable infectious diseases as per Ministry of Health announcements).

Where it's running

• China Medical University Hospital
  Taichung, Taiwan Recruiting

Study contacts

• Study coordinator: Der-Yuan Chen, M.D.;Ph.D
• Email: dychen1957@gmail.com
• Phone: 886-4-22052121

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early detection of progressive lung fibrosis in connective tissue diseases

  This project will test whether blood extracellular vesicle biomarkers combined with AI-analyzed HRCT scans can detect and predict progressive interstitial lung disease in adults with connective tissue diseases.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07541638

• Using capillaroscopy to help diagnose diffuse interstitial pneumonias

  We will test whether adding nailfold capillaroscopy to standard care helps doctors diagnose connective-tissue–related interstitial lung disease faster in adults newly diagnosed with pulmonary interstitial disease.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07283081

• Understanding genetic and environmental factors in pulmonary fibrosis

  This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.

  Recruiting Royal College of Surgeons, Ireland · Dublin · NCT06702228

• Registry of patients with connective tissue diseases and lung issues

  This study is collecting health information from patients with connective tissue diseases to see how often they develop lung problems and to understand their treatment over time.

  Recruiting Medical University Innsbruck · Innsbruck · NCT04095351

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.